Quick Summary
- Contract Value: $1.24 billion—the largest single contract for Samsung Biologics to date.
- Client: An Asia-based pharmaceutical company.
- Production Location: Songdo, South Korea, at Samsung Biologics’ biomanufacturing facility.
- Contract Duration: Extends through December 2037, contributing to Samsung’s $3.3 billion contract total for 2024.
Samsung Biologics, a leader in contract development and manufacturing (CDMO) services, announced a landmark $1.24 billion deal with an Asia-based pharmaceutical company on October 21, 2024. This record-breaking contract will leverage Samsung’s state-of-the-art facility in Songdo, South Korea, to manufacture high-quality biopharmaceuticals, a reflection of Samsung’s growing influence in global biomanufacturing.
Expanding Biomanufacturing Capacity
The new agreement bolsters Samsung Biologics’ manufacturing portfolio significantly, with the production timeline set to extend through 2037. This deal represents Samsung’s commitment to scaling up production capacity, a priority underscored by the recent completion of its fourth plant and ongoing construction of a fifth plant, which is slated to open in 2025. This expansion will increase Samsung’s total production capacity to 784,000 liters, positioning the company to better meet growing global demand.
John Rim, CEO of Samsung Biologics, noted that this strategic collaboration aligns with the company’s goals to deliver biopharmaceuticals on time and in full, ensuring reliability and efficiency for global clients. Samsung Biologics has built a strong reputation by partnering with top pharmaceutical companies worldwide, and this new contract highlights its ability to secure high-profile, long-term manufacturing deals.
Meeting Rising Demand for Biopharmaceuticals
With biopharmaceuticals rapidly growing as a sector, the demand for robust manufacturing capabilities is at an all-time high. Samsung’s investment in cutting-edge facilities, such as its upcoming antibody-drug conjugate (ADC) manufacturing capabilities and mRNA production lines, shows its dedication to supporting diverse biopharma needs.
As Samsung continues expanding its capabilities and securing major contracts, it aims to shape the biomanufacturing industry and support innovative therapies that address unmet global health needs.
References
